Summary
QDI Chart
Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease
Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J. , July 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test from Fujirebio, a global leader in the field of high-quality IVD testing.
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It?
DGX stock surges 27.3% in a year, fueled by Advanced Diagnostics, key acquisitions and expanding health plan ties.
4 Stocks to Watch in a Rapidly Shifting Outpatient Home Health Space
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, EHC, DVA and PNTG are well-poised to gain.
Quest Diagnostics Inc. (QDI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Quest Diagnostics Inc. ever had a stock split?
Quest Diagnostics Inc. Profile
| Medical - Diagnostics & Research Industry | Healthcare Sector | James E. Davis CEO | XSTU Exchange | US74834L1008 ISIN |
| US Country | 55,000 Employees | 7 Apr 2025 Last Dividend | 21 Jun 2005 Last Split | 17 Dec 1996 IPO Date |
Overview
Quest Diagnostics Incorporated, established in 1967 and based in Secaucus, New Jersey, is a prominent provider of diagnostic testing, information, and services both in the United States and internationally. The company operates with the mission to deliver critical diagnostic insights that lead to informed healthcare decisions. Using its extensive network of laboratories, patient service centers, and healthcare professionals, Quest Diagnostics offers a wide range of diagnostic information services. These services cater to a diverse clientele including physicians, hospitals, patients, health plans, government agencies, employers, and pharmaceutical companies. Through its flagship Quest Diagnostics brand and others such as AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum, the company aims to improve health outcomes by making better information available to the healthcare ecosystem.
Products and Services
- Diagnostic Information Services
- Risk Assessment Services for Life Insurance Industry
- Healthcare Information Technology Solutions
These encompass routine and non-routine clinical tests, advanced clinical testing, and anatomic pathology testing. Quest Diagnostics utilizes a vast array of technological platforms to provide critical diagnostic information that supports disease prevention, diagnosis, treatment, and management.
Quest Diagnostics provides comprehensive risk assessment services tailored to the needs of the life insurance sector. These services are designed to help insurance companies evaluate the health risks of policy applicants through a variety of diagnostic tests and assessments.
Offering cutting-edge information technology solutions, Quest Diagnostics helps healthcare organizations and clinicians enhance efficiency and patient care. These solutions encompass a wide range of IT services designed to facilitate the secure exchange of health information, improve lab ordering processes, and streamline patient record management.
Contact Information
